Literature DB >> 20947070

Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response.

Galit Eisenberg1, Arthur Machlenkin, Shoshana Frankenburg, Adva Mansura, Jacob Pitcovski, Eitan Yefenof, Tamar Peretz, Michal Lotem.   

Abstract

The objective of this study was to evaluate the potential of transcutaneous immunization with tumor antigen to induce cell-mediated immunity. For this purpose, hydrophilic recombinant gp100 protein (HR-gp100) was topically applied on human intact skin in vitro, and used as a vaccine in a mouse model. We demonstrate that HR-gp100 permeates into human skin, and is processed and presented by human dendritic cells. In a mouse model, an HR-gp100-based vaccine triggered antigen-specific T cell responses, as shown by proliferation assays, ELISA and intracellular staining for IFN-γ. Transcutaneous antigen delivery may provide a safe, simple and effective method to elicit cell-mediated immunity.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20947070      PMCID: PMC2976976          DOI: 10.1016/j.cellimm.2010.09.003

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  26 in total

1.  Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells.

Authors:  Anne-Sophie Beignon; Jean-Paul Briand; Sylviane Muller; Charalambos D Partidos
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

Review 2.  Immunity under the skin: potential application for topical delivery of vaccines.

Authors:  C D Partidos; A-S Beignon; F Mawas; G Belliard; J-P Briand; S Muller
Journal:  Vaccine       Date:  2003-01-30       Impact factor: 3.641

3.  Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis.

Authors:  N Seo; Y Tokura; T Nishijima; H Hashizume; F Furukawa; M Takigawa
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

4.  Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.

Authors:  John P Riley; Steven A Rosenberg; Maria R Parkhurst
Journal:  J Immunol Methods       Date:  2003-05-01       Impact factor: 2.303

5.  Recombinant hydrophilic human gp100: uptake by dendritic cells and stimulation of autologous CD8+ lymphocytes from melanoma patients.

Authors:  Shoshana Frankenburg; Orit Elias; Yamit Gelbart; Olga Drize; Michal Lotem; Arieh Ingber; Tamar Peretz; Jacob Pitcovski
Journal:  Immunol Lett       Date:  2004-07-15       Impact factor: 3.685

6.  Production and purification of melanoma gp100 antigen and polyclonal antibodies.

Authors:  Y Gelbart; S Frankenburg; Y Pinchasov; S Krispel; D Eliahu; O Drize; E Morag; D Bartfeld; M Lotem; T Peretz; J Pitcovski
Journal:  Protein Expr Purif       Date:  2004-04       Impact factor: 1.650

7.  Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues.

Authors:  Daniel J Campbell; Eugene C Butcher
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

8.  Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma.

Authors:  M Lotem; E Shiloni; I Pappo; O Drize; T Hamburger; R Weitzen; R Isacson; L Kaduri; S Merims; S Frankenburg; T Peretz
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

9.  Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.

Authors:  Gabrielle A Rizzuto; Taha Merghoub; Daniel Hirschhorn-Cymerman; Cailian Liu; Alexander M Lesokhin; Diana Sahawneh; Hong Zhong; Katherine S Panageas; Miguel-Angel Perales; Grégoire Altan-Bonnet; Jedd D Wolchok; Alan N Houghton
Journal:  J Exp Med       Date:  2009-03-30       Impact factor: 14.307

Review 10.  Immune surveillance in the skin: mechanisms and clinical consequences.

Authors:  Thomas S Kupper; Robert C Fuhlbrigge
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

View more
  4 in total

1.  Multi-compartmental vaccine delivery system for enhanced immune response to gp100 peptide antigen in melanoma immunotherapy.

Authors:  Mayurkumar Kalariya; Srinivas Ganta; Mansoor Amiji
Journal:  Pharm Res       Date:  2012-07-18       Impact factor: 4.200

2.  The effect of haptens on protein-carrier immunogenicity.

Authors:  Tal Gefen; Jacob Vaya; Soliman Khatib; Irena Rapoport; Meital Lupo; Eilon Barnea; Arie Admon; Elimelech Dan Heller; Elina Aizenshtein; Jacob Pitcovski
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

Review 3.  Cancer immunotherapy: broadening the scope of targetable tumours.

Authors:  Jitske van den Bulk; Els Me Verdegaal; Noel Fcc de Miranda
Journal:  Open Biol       Date:  2018-06       Impact factor: 6.411

4.  Prognostic value of B cells in cutaneous melanoma.

Authors:  Sara R Selitsky; Lisle E Mose; Christof C Smith; Shengjie Chai; Katherine A Hoadley; Dirk P Dittmer; Stergios J Moschos; Joel S Parker; Benjamin G Vincent
Journal:  Genome Med       Date:  2019-05-28       Impact factor: 11.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.